Table 3.

Summary of the log-normalized ratio of PL-ASA to IR-ASA for statistics based on inhibition of TxB2 (325 and 650 mg doses)

	PL-ASAa	IR-ASA	Ratiob (%)	90% CIc	ANOVA P valued
325 mg dose
AUC0-t (% inh×min)	125,379.4	125,241.6	100.28	98.88–101.69	0.6702
Imax (%)	99.9	100.0	99.94	99.81–100.07	0.4281
650 mg dose
AUC0-t (% inh×min)	125,078.9	123,921.1	100.56	97.00–104.26	0.7536
Imax (%)	100.0	100.0	100.0	100.00–100.00	–

Source: Angiolillo et al. [46]

ANOVA analysis of variance, AUC_0-t area under the curve from time zero to the last measurable concentration, CI confidence interval, I_max maximum inhibition, inh inhibition, IR-ASA immediate-release aspirin, PL-ASA phospholipid-aspirin complex, TxB2 thromboxane B2

^aValues are geometric means

^bRatio = 100 × geometric mean (PL-ASA)/geometric mean (IR-ASA)

^c90% confidence interval on the ratio of PL-ASA to IR-ASA

^dp value for the difference in the treatment estimates; significant difference is defined as a p value < 0.05